Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment

Neurology. 2009 Sep 22;73(12):991-3. doi: 10.1212/WNL.0b013e3181b878f6.

Authors

J Dörr¹, A Bitsch, K J G Schmailzl, A Chan, N von Ahsen, M Hummel, R Varon, C M Lill, H-P Vogel, F Zipp, Friedemann Paul

Affiliation

¹ NeuroCure Clinical Research Center, Charité-Universitaetsmedizin Berlin, 10117 Berlin, Germany.

PMID: 19770476
DOI: 10.1212/WNL.0b013e3181b878f6

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

ATP Binding Cassette Transporter, Subfamily B
ATP Binding Cassette Transporter, Subfamily B, Member 1 / genetics
ATP Binding Cassette Transporter, Subfamily G, Member 2
ATP-Binding Cassette Transporters / genetics
Adult
Antineoplastic Agents / adverse effects
Cardiomyopathies / chemically induced*
Cardiomyopathies / physiopathology
Collagen Type III / analysis
Collagen Type III / metabolism
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Resistance / genetics
Female
Genetic Predisposition to Disease
Heart Failure / chemically induced*
Heart Failure / physiopathology
Humans
Mitoxantrone / adverse effects*
Multiple Sclerosis / drug therapy*
Myocardium / metabolism
Myocardium / pathology
Neoplasm Proteins / genetics
Polymorphism, Genetic / genetics
Pulmonary Edema / chemically induced
Pulmonary Edema / physiopathology
Ventricular Dysfunction, Left / chemically induced
Ventricular Dysfunction, Left / physiopathology

Substances

ABCB1 protein, human
ABCG2 protein, human
ATP Binding Cassette Transporter, Subfamily B
ATP Binding Cassette Transporter, Subfamily B, Member 1
ATP Binding Cassette Transporter, Subfamily G, Member 2
ATP-Binding Cassette Transporters
Antineoplastic Agents
Collagen Type III
Neoplasm Proteins
Mitoxantrone